Boston Scientific's Commentary on M&A
"Near term, our capital allocation priorities are to prepay debt, manage our contingencies, and pursue tuck-in M&A."
Daniel Brennan, Boston Scientific CFO, according to a Seeking Alpha transcript of the company's first quarter earnings call
Get inspired to innovate in medtech at the MD&M East Conference, June 14-16, in New York City.
[Image courtesy of STUART MILES/FREEDIGITALPHOTOS.NET]